Neuphoria Therapeutics Inc
Research Neuphoria Therapeutics Inc (NEUP) on Bullrun: market cap USD 17.97M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNEUP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 17.97M
- Financial periodFY2026
- RevenueUSD 1.17M
- Revenue growth-92.5%
- Net income-USD 13.45M
- Free cash flow-USD 12.35M
Valuation Snapshot
latest market cap is USD 17.97M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 1.17M | -USD 13.45M | -USD 12.35M | n/a | n/a | USD 19.87M | USD 34.35K | USD 24.60M |
| FY2025 | USD 15.65M | -USD 400.00K | n/a | n/a | -0.23 | USD 14.21M | USD 33.47K | USD 19.00M |
| FY2024 | USD 0 | -USD 15.49M | -USD 14.68M | n/a | -18.62 | USD 12.61M | USD 272.74K | USD 17.49M |
| FY2023 | USD 0 | -USD 21.38M | -USD 14.64M | n/a | -0.02 | USD 12.10M | USD 386.92K | USD 22.01M |
| FY2022 | USD 181.36K | -USD 14.97M | -USD 14.97M | n/a | -0.17 | USD 23.09M | USD 477.15K | USD 39.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 17.97M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 20.86M | 29.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.59M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 26.08B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 75.52B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 197.22B | n/a | n/a | n/a |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neuphoria Therapeutics Inc's market cap?
Neuphoria Therapeutics Inc's market capitalization is USD 17.97M.
What does Neuphoria Therapeutics Inc do?
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc.